TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Prostate Cancer Nuclear Medicine Diagnostics Market Research Report 2023

Global Prostate Cancer Nuclear Medicine Diagnostics Market Research Report 2023

  • Category:Life Sciences
  • Published on : 01 May 2023
  • Pages :88
  • Formats:
  • Report Code:SMR-7666072
OfferClick for best price

Best Price: $2320

Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share 2023


Market Analysis and Insights: Global Prostate Cancer Nuclear Medicine Diagnostics Market

The global Prostate Cancer Nuclear Medicine Diagnostics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Prostate Cancer Nuclear Medicine Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Prostate Cancer Nuclear Medicine Diagnostics market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Prostate Cancer Nuclear Medicine Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Prostate Cancer Nuclear Medicine Diagnostics market.

Global Prostate Cancer Nuclear Medicine Diagnostics Scope and Market Size

Prostate Cancer Nuclear Medicine Diagnostics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Prostate Cancer Nuclear Medicine Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.

Segment by Type

SPECT

PET

Segment by Application

Hospitals

Clinics

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Blue Earth Diagnostics

PETNET Solutions

Cardinal Health

Lantheus Medical Imaging

Jubilant Pharma

NCM-USA

Progenics Pharma

Telix Pharma

ImaginAb

Theragnostics

Novartis

Alliance Medical

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Prostate Cancer Nuclear Medicine Diagnostics product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Prostate Cancer Nuclear Medicine Diagnostics, with price, sales, revenue, and global market share of Prostate Cancer Nuclear Medicine Diagnostics from 2019 to 2022.

Chapter 3, the Prostate Cancer Nuclear Medicine Diagnostics competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Prostate Cancer Nuclear Medicine Diagnostics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Prostate Cancer Nuclear Medicine Diagnostics market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Prostate Cancer Nuclear Medicine Diagnostics.

Chapter 13, 14, and 15, to describe Prostate Cancer Nuclear Medicine Diagnostics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Prostate Cancer Nuclear Medicine Diagnostics Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Prostate Cancer Nuclear Medicine Diagnostics Market Research Report 2023
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2022
Forecast Year 2030
Number of Pages 88 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 SPECT
1.2.3 PET
1.3 Market by Application
1.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Perspective (2018-2029)
2.2 Prostate Cancer Nuclear Medicine Diagnostics Growth Trends by Region
2.2.1 Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Region (2024-2029)
2.3 Prostate Cancer Nuclear Medicine Diagnostics Market Dynamics
2.3.1 Prostate Cancer Nuclear Medicine Diagnostics Industry Trends
2.3.2 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
2.3.3 Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
2.3.4 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue
3.1.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Cancer Nuclear Medicine Diagnostics Revenue
3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio
3.4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2022
3.5 Prostate Cancer Nuclear Medicine Diagnostics Key Players Head office and Area Served
3.6 Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
3.7 Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Type
4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2024-2029)
5 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Application
5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2018-2029)
6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023)
6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size (2018-2029)
7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023)
7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size (2018-2029)
8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023)
8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2018-2029)
9.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023)
9.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size (2018-2029)
10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023)
10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Blue Earth Diagnostics
11.1.1 Blue Earth Diagnostics Company Detail
11.1.2 Blue Earth Diagnostics Business Overview
11.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.1.4 Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.1.5 Blue Earth Diagnostics Recent Development
11.2 PETNET Solutions
11.2.1 PETNET Solutions Company Detail
11.2.2 PETNET Solutions Business Overview
11.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.2.4 PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.2.5 PETNET Solutions Recent Development
11.3 Cardinal Health
11.3.1 Cardinal Health Company Detail
11.3.2 Cardinal Health Business Overview
11.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.3.4 Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.3.5 Cardinal Health Recent Development
11.4 Lantheus Medical Imaging
11.4.1 Lantheus Medical Imaging Company Detail
11.4.2 Lantheus Medical Imaging Business Overview
11.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.4.4 Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.4.5 Lantheus Medical Imaging Recent Development
11.5 Jubilant Pharma
11.5.1 Jubilant Pharma Company Detail
11.5.2 Jubilant Pharma Business Overview
11.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.5.4 Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.5.5 Jubilant Pharma Recent Development
11.6 NCM-USA
11.6.1 NCM-USA Company Detail
11.6.2 NCM-USA Business Overview
11.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.6.4 NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.6.5 NCM-USA Recent Development
11.7 Progenics Pharma
11.7.1 Progenics Pharma Company Detail
11.7.2 Progenics Pharma Business Overview
11.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.7.4 Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.7.5 Progenics Pharma Recent Development
11.8 Telix Pharma
11.8.1 Telix Pharma Company Detail
11.8.2 Telix Pharma Business Overview
11.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.8.4 Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.8.5 Telix Pharma Recent Development
11.9 ImaginAb
11.9.1 ImaginAb Company Detail
11.9.2 ImaginAb Business Overview
11.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.9.4 ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.9.5 ImaginAb Recent Development
11.10 Theragnostics
11.10.1 Theragnostics Company Detail
11.10.2 Theragnostics Business Overview
11.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.10.4 Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.10.5 Theragnostics Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.11.4 Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.11.5 Novartis Recent Development
11.12 Alliance Medical
11.12.1 Alliance Medical Company Detail
11.12.2 Alliance Medical Business Overview
11.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.12.4 Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
11.12.5 Alliance Medical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of SPECT
Table 3. Key Players of PET
Table 4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Region (2018-2023)
Table 8. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Region (2024-2029)
Table 10. Prostate Cancer Nuclear Medicine Diagnostics Market Trends
Table 11. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
Table 12. Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
Table 13. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
Table 14. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Players (2018-2023)
Table 16. Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Nuclear Medicine Diagnostics as of 2022)
Table 17. Ranking of Global Top Prostate Cancer Nuclear Medicine Diagnostics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
Table 21. Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2018-2023)
Table 25. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2024-2029)
Table 27. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2018-2023)
Table 29. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2024-2029)
Table 31. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 34. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 35. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 36. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2024-2029) & (US$ Million)
Table 37. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 40. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2024-2029) & (US$ Million)
Table 41. Blue Earth Diagnostics Company Detail
Table 42. Blue Earth Diagnostics Business Overview
Table 43. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product
Table 44. Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 45. Blue Earth Diagnostics Recent Development
Table 46. PETNET Solutions Company Detail
Table 47. PETNET Solutions Business Overview
Table 48. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product
Table 49. PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 50. PETNET Solutions Recent Development
Table 51. Cardinal Health Company Detail
Table 52. Cardinal Health Business Overview
Table 53. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product
Table 54. Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 55. Cardinal Health Recent Development
Table 56. Lantheus Medical Imaging Company Detail
Table 57. Lantheus Medical Imaging Business Overview
Table 58. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product
Table 59. Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 60. Lantheus Medical Imaging Recent Development
Table 61. Jubilant Pharma Company Detail
Table 62. Jubilant Pharma Business Overview
Table 63. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product
Table 64. Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 65. Jubilant Pharma Recent Development
Table 66. NCM-USA Company Detail
Table 67. NCM-USA Business Overview
Table 68. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product
Table 69. NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 70. NCM-USA Recent Development
Table 71. Progenics Pharma Company Detail
Table 72. Progenics Pharma Business Overview
Table 73. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product
Table 74. Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 75. Progenics Pharma Recent Development
Table 76. Telix Pharma Company Detail
Table 77. Telix Pharma Business Overview
Table 78. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product
Table 79. Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 80. Telix Pharma Recent Development
Table 81. ImaginAb Company Detail
Table 82. ImaginAb Business Overview
Table 83. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product
Table 84. ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 85. ImaginAb Recent Development
Table 86. Theragnostics Company Detail
Table 87. Theragnostics Business Overview
Table 88. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product
Table 89. Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 90. Theragnostics Recent Development
Table 91. Novartis Company Detail
Table 92. Novartis Business Overview
Table 93. Novartis Prostate Cancer Nuclear Medicine DiagnosticsProduct
Table 94. Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Alliance Medical Company Detail
Table 97. Alliance Medical Business Overview
Table 98. Alliance Medical Prostate Cancer Nuclear Medicine DiagnosticsProduct
Table 99. Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023) & (US$ Million)
Table 100. Alliance Medical Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type: 2022 VS 2029
Figure 2. SPECT Features
Figure 3. PET Features
Figure 4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application in 2022 & 2029
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Prostate Cancer Nuclear Medicine Diagnostics Report Years Considered
Figure 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 10. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 11. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Region: 2022 VS 2029
Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Players in 2022
Figure 13. Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Nuclear Medicine Diagnostics as of 2022)
Figure 14. The Top 10 and 5 Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2022
Figure 15. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 16. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2018-2029)
Figure 17. United States Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2018-2029)
Figure 21. Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. France Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. U.K. Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Nordic Countries Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Share by Region (2018-2029)
Figure 29. China Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. India Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Australia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2018-2029)
Figure 37. Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2018-2029)
Figure 41. Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Blue Earth Diagnostics Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 44. PETNET Solutions Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 45. Cardinal Health Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 46. Lantheus Medical Imaging Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 47. Jubilant Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 48. NCM-USA Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 49. Progenics Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 50. Telix Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 51. ImaginAb Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 52. Theragnostics Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 53. Novartis Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 54. Alliance Medical Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount